Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Pharmaceutical Holding Company Ltd (NY: BHVN )

77.84 USD +1.80 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biohaven Pharmaceutical Holding Company Ltd

< Previous 1 2 3 4 5 6 Next >
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season. The first... 
From PR Newswire
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of... 
From PR Newswire
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
- Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule... 
From PR Newswire
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona.... 
From PR Newswire
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
- Recently completed Phase 2 proof of concept study showed drug signal for troriluzole augmentation in OCD and pivotal Phase 3 trial now initiated 
From PR Newswire
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
- Rimegepant 75 mg, already approved for the acute treatment of migraine, demonstrated efficacy and safety for the preventive treatment of migraine in this pivotal Phase 3 trial in adults 
From PR Newswire
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American
Proof-of-Concept Data Demonstrates Broad Therapeutic Potential of Company’s Multi-targeted Antibody Therapy Enhancer (MATE™) Platform 
From GlobeNewswire News Releases
Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series
Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry during the entire 2021 NASCAR Cup Series Season,... 
From PR Newswire
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
- Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists 
From PR Newswire
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
From GlobeNewswire News Releases
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
From GlobeNewswire News Releases
Value-based agreement between Prime Therapeutics and Biohaven aims to bring NURTEC™ ODT acute migraine treatment financial protection to health plans
Quick-dissolve NURTEC ODT can help bring relief to patients within an hour1 
From PR Newswire
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
- Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque... 
From PR Newswire
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
- National Ataxia Foundation (NAF) Drug Development Collaborative to cultivate resources that facilitate research and development of new potential treatments for Ataxia, a set of severe and... 
From PR Newswire
Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE™) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting
From GlobeNewswire News Releases
Biohaven Reports Third Quarter 2020 Financial Results and Recent Business Developments
- NURTEC™ ODT (rimegepant) achieved net revenues of $17.7 million for the third quarter of 2020, representing an over 80% increase in net revenues from the second quarter of this year 
From PR Newswire
Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and... 
From PR Newswire
Kleo Pharmaceuticals Announces Data Presentation on Novel Conjugation Platform at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting
From GlobeNewswire News Releases
U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine
Acceptance marks critical milestone in Biohaven's efforts to develop NURTEC ODT as a unique dual therapy for both the preventive and acute treatment of migraine 
From PR Newswire
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
- Initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20 
From PR Newswire
Kleo Pharmaceuticals to Present at “Bioscience Pipeline & Innovation in Connecticut in the Age of COVID” Conference
From GlobeNewswire News Releases
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
- Investigational New Drug (IND) application was authorized to proceed by the US FDA for human dosing with oral zavegepant 
From PR Newswire
Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma
CD38-Targeting Molecule To be Evaluated in Multiple Patient Populations 
From GlobeNewswire News Releases
Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments
- NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share 
From PR Newswire
Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street
- Strategic, Non-Dilutive, Growth Capital Supports Commercialization of NURTEC™ ODT and Company's Pipeline Development 
From PR Newswire
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
From GlobeNewswire News Releases
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
- Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications 
From PR Newswire
Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and... 
From PR Newswire
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital
- Biohaven's verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH 
From PR Newswire
Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy
- Multiple System Atrophy (MSA) is a rare, relentlessly progressive and fatal neurodegenerative disease 
From PR Newswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.